Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARNA Arena Pharmaceuticals	$99.99	$97.65	$45.50 ▼ $100.00	$6.17B	0.55	1.56 million shs	107 shs
ARQL ArQule	$20.00	$20.00	$3.15 ▼ $20.45	$2.42B	2.49	5.27 million shs	N/A
BHVN Biohaven	$13.90 +0.8%	$16.58	$13.75 ▼ $55.70	$1.42B	0.91	1.29 million shs	1.11 million shs
INSM Insmed	$96.14 -0.8%	$81.42	$60.40 ▼ $106.83	$18.24B	0.9	2.30 million shs	1.91 million shs
QURE uniQure	$14.44 +0.9%	$14.54	$3.76 ▼ $19.18	$791.02M	0.08	1.96 million shs	704,160 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARNA Arena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ARQL ArQule	0.00%	0.00%	0.00%	0.00%	0.00%
BHVN Biohaven	-5.60%	-2.13%	-18.72%	-16.45%	-59.47%
INSM Insmed	-1.57%	-3.67%	+31.69%	+49.22%	+38.50%
QURE uniQure	-1.21%	+2.65%	-17.14%	+71.58%	+272.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARQL ArQule	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	3.188 of 5 stars	4.5	1.0	0.0	0.0	1.8	2.5	0.6
INSM Insmed	4.5613 of 5 stars	3.5	4.0	0.0	4.3	3.4	1.7	0.6
QURE uniQure	2.1195 of 5 stars	3.5	1.0	0.0	0.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARNA Arena Pharmaceuticals	0.00	N/A	N/A	N/A
ARQL ArQule	0.00	N/A	N/A	N/A
BHVN Biohaven	3.07	Buy	$58.46	320.59% Upside
INSM Insmed	3.00	Buy	$108.07	12.41% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	161.90% Upside

Current Analyst Ratings Breakdown

Latest INSM, QURE, ARNA, ARQL, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00
6/11/2025	INSM Insmed	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$94.00 ➝ $109.00
6/11/2025	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $120.00
6/10/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	INSM Insmed	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARNA Arena Pharmaceuticals	$50K	123,305.67	N/A	N/A	$10.94 per share	9.14
ARQL ArQule	$25.76M	93.85	N/A	N/A	$0.72 per share	27.78
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
INSM Insmed	$381.03M	47.87	N/A	N/A	$1.60 per share	60.09
QURE uniQure	$27.12M	29.17	N/A	N/A	($0.14) per share	-103.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARNA Arena Pharmaceuticals	-$616.43M	-$10.13	N/A	N/A	N/A	N/A	-69.83%	-62.35%	N/A
ARQL ArQule	-$15.48M	-$0.16	N/A	N/A	N/A	-805.61%	-33.10%	-26.87%	N/A
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)

Latest INSM, QURE, ARNA, ARQL, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARQL ArQule	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARNA Arena Pharmaceuticals	0.05	8.59	8.59
ARQL ArQule	0.08	8.27	8.27
BHVN Biohaven	N/A	2.33	2.33
INSM Insmed	11.38	5.86	5.44
QURE uniQure	1.53	11.99	11.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARNA Arena Pharmaceuticals	83.77%
ARQL ArQule	74.63%
BHVN Biohaven	88.78%
INSM Insmed	N/A
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ARNA Arena Pharmaceuticals	2.41%
ARQL ArQule	13.80%
BHVN Biohaven	14.60%
INSM Insmed	3.00%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARNA Arena Pharmaceuticals	448	61.66 million	60.17 million	Optionable
ARQL ArQule	36	120.87 million	N/A	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable

INSM, QURE, ARNA, ARQL, and BHVN Headlines

Recent News About These Companies

uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 3, 2025 | americanbankingnews.com

uniQure (NASDAQ:QURE) Stock Crosses Below 50-Day Moving Average - Should You Sell?

July 2, 2025 | americanbankingnews.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

February 27, 2025 | globenewswire.com

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

February 7, 2025 | benzinga.com

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

February 7, 2025 | prnewswire.com

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

February 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Russell Rebalance: 3 Stocks Ready to Move Higher
By Chris Markoch | June 20, 2025
View Russell Rebalance: 3 Stocks Ready to Move Higher

INSM, QURE, ARNA, ARQL, and BHVN Company Descriptions

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

ArQule NASDAQ:ARQL

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Biohaven NYSE:BHVN

$13.90 +0.11 (+0.80%)

Closing price 03:59 PM Eastern

Extended Trading

$13.99 +0.09 (+0.65%)

As of 06:20 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Insmed NASDAQ:INSM

$96.14 -0.81 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$98.88 +2.75 (+2.86%)

As of 06:21 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

uniQure NASDAQ:QURE

$14.44 +0.13 (+0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$14.56 +0.12 (+0.83%)

As of 05:02 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time